Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.52 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 4/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | POLA1 | P09884 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28851524 | 1.00 | ACE2 (0.52) | ACE2ZDHHC7MEN1HPGDRECQL | |
| SCHEMBL28333296 | 1.00 | ACE2 (0.52) | ACE2ZDHHC7MEN1HPGDRECQL | |
| SCHEMBL2254424 | 1.00 | ACE2 (0.52) | ACE2ZDHHC7MEN1HPGDRECQL | |
| SCHEMBL13610030 | 0.98 | ACE2 (0.48) | ACE2ZDHHC7MEN1HPGDRECQL | |
| SCHEMBL10682889 | 0.92 | CA2 (0.47) | ACE2ZDHHC7MEN1HPGDRECQL | |
| SCHEMBL31011228 | 0.92 | CA2 (0.47) | ACE2ZDHHC7MEN1HPGDRECQL | |
| SCHEMBL14651155 | 0.92 | CA2 (0.47) | ACE2ZDHHC7MEN1HPGDRECQL | |
| SCHEMBL31508747 | 0.91 | ACE2 (0.47) | ACE2ZDHHC7MEN1HPGDRECQL | |
| SCHEMBL27557979 | 0.86 | CNR1 (0.51) | HPGDFAAHCNR1CNR2 | |
| SCHEMBL16341622 | 0.85 | ACE2 (0.52) | ACE2ZDHHC7FAAHCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180028649-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2018-02-01 | — | — | US | disclosed |
| US-9814772-B2 | Synthetic glucopyranosyl lipid adjuvants | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170182155-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | INFECTIOUS DISEASE RES INST (US) | 2017-06-29 | — | — | US | disclosed |
| US-9480740-B2 | Synthetic glucopyranosyl lipid adjuvants | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2016-11-01 | — | — | US | disclosed |
| US-20140322268-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140322268-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | B3GAT3, GLA, LGALS8 | ACE2 1201/4885ZDHHC7 804/4885MEN1 3263/4885 |
| US-20180028649-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | B3GAT3, GLA, LGALS8 | ACE2 1174/4885ZDHHC7 835/4885MEN1 3305/4885 |
| US-20170182155-A1 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS | B3GAT3, GLA, LGALS8 | ACE2 1201/4885ZDHHC7 804/4885MEN1 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.